PROCARDIS is a multi-centre study designed to identify susceptibility genes for coronary artery disease (CAD) through the exploitation of complex trait genetics and functional genomics. It is a collaborative study involving a network of academic groups and biotechnical/pharmaceutical research partners based in a number of European countries. The study, which is funded by the European Commission, is co-ordinated by the Department of Cardiovascular Medicine, University of Oxford and is made up of partners in Sweden, Germany, Italy, United Kingdom, France, and Spain.

The pathogenesis of CAD has been shown by twin and other studies to include a significant genetic component and it is known that the effects of genes on susceptibility to CAD are particularly strong at younger ages. CAD is not inherited as a simple Mendelian trait, but is a complex multifactorial disorder heavily influenced by environmental as well as genetic factors, making dissection of the genetic contribution complicated. The aim of the Procardis team is to use genomic approaches to find ways of defining new targets for prevention and treatment of coronary artery disease and to devise diagnostic tools that identify disease mechanisms in individuals.

To complement the scientific research of the Procardis network, Paula Boddington and Michael Parker are carrying out a three year research project (2007-2010) to identify and analyse the ethical issues likely to arise in the translation of this genetic research into clinical practice. It is likely that these will include: the identification of risk factors at young ages, questions about who should be tested, what should happen to information, and confidentiality issues.

For more information about this research contact Paula Boddington at the Ethox Centre.